Mujahid Edy Husnul, Limoa Erlyn, Syamsuddin Saidah, Bahar Burhanuddin, Renaldi Rinvil, Aminuddin Aminuddin, Lisal Sonny T
Department of Psychiatry, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
Indonesia & Faculty of Medicine, Halu Oleo University, Kendari, Indonesia.
Psychiatry Investig. 2022 Nov;19(11):898-908. doi: 10.30773/pi.2022.0064. Epub 2022 Nov 23.
This study aims to examine the effect of giving probiotic adjuvant therapy on improving clinical symptoms & IL-6 levels in patients with schizophrenia.
This research was a double-blind, placebo-controlled trial conducted at Dadi Psychiatric Hospital, South Sulawesi Province, Indonesia in November-December 2021. The sample of the research was patients with schizophrenia undergoing hospitalization who received therapeutic doses of risperidone with a total of 21 samples in each treatment and control group. Research subjects were measured with Positive and Negative Syndrome Scale (PANSS) at baseline, 2nd, 4th, and 6th weeks. The treatment group received one capsule/12 hours/oral of probiotics for six weeks and the control group received 1 capsule/12 hours/oral placebo for 6 weeks. In addition, two measurements of IL-6 using enzyme-linked immunosorbent assay were performed in both groups, namely at the beginning of week 0 and the end of the 6th week.
We found the decrease in the PANSS value which described the improvement in clinical symptoms of the schizophrenic group after receiving therapeutic doses of antipsychotics and probiotic capsules or the treatment group as well as the schizophrenia group receiving therapeutic doses of antipsychotics and placebo capsules or the control group.
Improvements in clinical symptoms and decreased levels of IL-6 in the group of patients with schizophrenia who received risperidone with probiotic adjuvant therapy were better than in the group of patients with schizophrenia who received risperidone without probiotics as adjuvant therapy.
本研究旨在探讨给予益生菌辅助治疗对改善精神分裂症患者临床症状及白细胞介素 -6（IL-6）水平的影响。
本研究为双盲、安慰剂对照试验，于2021年11月至12月在印度尼西亚南苏拉威西省大地精神病医院进行。研究样本为正在住院的精神分裂症患者，每个治疗组和对照组各有21个样本，均接受治疗剂量的利培酮。在基线、第2周、第4周和第6周，使用阳性和阴性症状量表（PANSS）对研究对象进行测量。治疗组接受益生菌胶囊，口服1粒/12小时，共六周；对照组接受安慰剂胶囊，口服1粒/12小时，共六周。此外，两组均在第0周开始和第6周结束时使用酶联免疫吸附测定法进行两次IL-6测量。
我们发现，接受治疗剂量抗精神病药物及益生菌胶囊的精神分裂症组（即治疗组），以及接受治疗剂量抗精神病药物及安慰剂胶囊的精神分裂症组（即对照组），其PANSS值均下降，这表明临床症状有所改善。
接受利培酮加益生菌辅助治疗的精神分裂症患者组，其临床症状改善及IL-6水平降低的情况优于接受利培酮但无益生菌辅助治疗的精神分裂症患者组。
